{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35872347",
  "DateCompleted": {
    "Year": "2022",
    "Month": "08",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "09",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "07",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.bmc.2022.116914",
      "S0968-0896(22)00307-8"
    ],
    "Journal": {
      "ISSN": "1464-3391",
      "JournalIssue": {
        "Volume": "70",
        "PubDate": {
          "Year": "2022",
          "Month": "Sep",
          "Day": "15"
        }
      },
      "Title": "Bioorganic & medicinal chemistry",
      "ISOAbbreviation": "Bioorg Med Chem"
    },
    "ArticleTitle": "Exploring the roles of the Cdc2-like kinases in cancers.",
    "Pagination": {
      "StartPage": "116914",
      "MedlinePgn": "116914"
    },
    "Abstract": {
      "AbstractText": [
        "The Cdc2-like kinases (CLKs 1-4) are involved in regulating the alternative splicing of a variety of genes. Their activity contributes to important cellular processes such as proliferation, differentiation, apoptosis, migration, and cell cycle regulation. Abnormal expression of CLKs can lead to cancers; therefore, pharmacological inhibition of CLKs may be a useful therapeutic strategy. This review summarises what is known about the roles of each of the CLKs in cancerous cells, as well as the effects of relevant small molecule CLK inhibitors."
      ],
      "CopyrightInformation": "Copyright \u00a9 2022 Elsevier Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand."
          }
        ],
        "LastName": "Blackie",
        "ForeName": "Alexis C",
        "Initials": "AC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand. Electronic address: daniel.foley@canterbury.ac.nz."
          }
        ],
        "LastName": "Foley",
        "ForeName": "Daniel J",
        "Initials": "DJ"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Bioorg Med Chem",
    "NlmUniqueID": "9413298",
    "ISSNLinking": "0968-0896"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EC 2.7.10.1",
      "NameOfSubstance": "Protein-Tyrosine Kinases"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "Protein Serine-Threonine Kinases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Alternative Splicing"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Phosphorylation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Serine-Threonine Kinases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein-Tyrosine Kinases"
    }
  ]
}